Press Releases

DiaCarta Named to CIO Applications’ “Top 25 Life Sciences Technology Vendors 2018”

CIO Applications has chosen DiaCarta as one of the Top 25 Life Sciences Technology Vendors 2018. The positioning is based on an evaluation of DiaCarta’s specialty in personalized diagnostics, translational genomics and clinical sample testing services provided in both US and China.
Read More
DiaCarta: Democratizing the Diagnosis Process
Blog

DiaCarta: Democratizing the Diagnosis Process

Read More
Press Releases

DiaCarta and MIODx Join Forces to Develop a Diagnostic Test to Predict Patient Responses to Immunotherapy

MIODx and DiaCarta announced today that they have entered into an agreement for the development of a diagnostic test for immunotherapy. The test is based on MIODx’s ClonoMap™ immune sequencing platform, and is designed to predict patient response to immunotherapy, which will be developed and validated at DiaCarta’s CLIA labs in both the San Francisco Bay Area and Nanjing, China.
Read More
Press Releases

DiaCarta, Ltd Raises $45 Million USD Series B Funding to Expand Its Liquid Biopsy Cancer Detection Platform & Services

DiaCarta has announced that it has completed its Series B funding round, realizing a total of $45.0M USD. The second closing was led by Fortune Fountain Capital (FFC) and was also subscribed to by Good Health Capital (GHC).
Read More
DiaCarta Demos Liquid Biopsy Use for ColoScape Assay, Plans to Market Expanded Application
Blog

DiaCarta Demos Liquid Biopsy Use for ColoScape Assay, Plans to Market Expanded Application

Read More
Publications

Reducing Artifactual EGFR T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA Glycosylase

Abstract: Both U:G and T:G lesions in formalinfixed tissue are sources of false-positive EGFR T790M mutations. This is the first report of the use of TDG to reduce sequence artifacts in formalin-fixed DNA and is applicable to the accurate detection of mutations arising at methylated cytosines. Authors: Hongdo Do, Ramyar Molania, Paul L. Mitchell, Rita Vaiskunaite, John D. Murdoch, and Alexander Dobrovic Source: Clinical Chemistry 63:9 000–000 (2017) Molecular Diagnostics and Genetics 000–000 (2017), doi:10.1373/clinchem.2017.271932
Read More
Press Releases

DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test – ColoScape™ Real-Time PCR Kit

ColoScape™ offers high sensitivity and accuracy of detection for clinically validated colorectal cancer mutations in DNA extracted from solid tumor, plasma or stool samples.
Read More
Press Releases

DiaCarta Receives NCI Contract for a Circulating Free DNA (cfDNA) Test to Monitor Radiation Response in Cancer Patients

California-based molecular diagnostics company DiaCarta, Inc., has received a SBIR contract from the National Cancer Institute (NCI). This contract will fund a collaborative program between DiaCarta and University of Florida Health Cancer Center to convert RadTox QuantiDNATM into a cutting-edge test that monitors radiation response in cancer patients.
Read More
Press Releases

DiaCarta Introduces QFusion™ Single-Tube qPCR Assay for ALK Fusion Gene Detection

DiaCarta today announced the introduction of QFusionTM RT-qPCR assay, a new product for the comprehensive, rapid and reliable detection of ALK fusion gene variants. The assay enables users to detect ten EML4-ALK and three KIF5B-ALK fusion gene variants in a single tube of multiplexed reactions with only 50 ng of RNA from FFPE samples in approximately 1.5 hours.
Read More
Press Releases

DiaCarta Receives ISO 13485:2003 Certification

DiaCarta, an innovator in precision molecular diagnostics, today announced that the company has received ISO 13485:2003 certification for the design, manufacture and distribution of its diagnostic and molecular genetic testing kits.
Read More
Press Releases

DiaCarta and Pangaea Biotech Join Forces to Launch Non-Invasive Tests to Detect Genetic Mutations in Blood from Cancer Patients

DiaCarta and Pangaea Biotech S.L have signed a long term agreement to launch in the U.S.A and China a non-invasive test to detect genetic material in blood of cancer patients, a technique known as ‘liquid biopsy’.
Read More
Press Releases

DiaCarta Clinical Services Laboratory Receives CLIA Certification

DiaCarta, an innovative translational genomics and precision molecular diagnostics company, today announced that DiaCarta Clinical Services Laboratory (DCSL) successfully passed the State of California survey under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
Read More
Press Releases

DiaCarta Obtains Exclusive License for Non-Invasive Early Detection Colon Cancer Test

DIACARTA INC. ("DIACARTA") and UNIVERSITY OF POTSDAM (Germany) today announced that the parties have entered into an exclusive license agreement for the development and commercialization of non-invasive early detection of colon cancer from stool samples.
Read More
Press Releases

DiaCarta, Inc Closes $8 Million Series A Round for Development and Commercialization of Precision Molecular Diagnostics

DiaCarta, Inc. raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors.
Read More
Press Releases

DiaCarta Inc. Receives CE Mark for Its Proprietary IVD Cancer Mutation Tests: KRAS, NRAS, EGFR and More

DiaCarta Inc., a technology driven translational genomics and molecular diagnostics company, today announced it has received CE Mark for its proprietary IVD cancer mutation tests QClamp™ KRAS including codon 146 and 117, NRAS including codon 146, EGFR including T790M, all deletions and insertions, BRAF, JAK2 and PIK3CA. These highly sensitive mutation tests suppress PCR amplification of wild-type template DNA and allows selective PCR amplification of only mutant templates, which can derive results in 2 hours directly from samples including FFPE and liquid biopsy without DNA purification on any commercial available Real-Time PCR machines.
Read More
Press Releases

DiaCarta Inc. Launches QClamp™ Somatic Mutation Real-Time PCR Tests for KRAS, NRAS, EGFR, BRAF, PIK3CA and More Without DNA Extractions

DiaCarta today announced it has launched its QClamp™ somatic mutation tests, highly sensitive and rapid tests for KRAS, NRAS, EGFR, BRAF, PIK3CA and more in 2 hours without DNA extraction.
Read More

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X